Form 4: Cartesian Therapeutics CEO Sells Shares for Tax

Cartesian Therapeutics' President and CEO, Carsten Brunn, sold 23,766 shares of common stock to cover tax obligations and broker fees.

Summary

• Carsten Brunn, President and CEO of Cartesian Therapeutics, Inc. (RNAC), reported a sale of common stock.
• The transaction involved the disposition of 23,766 shares of common stock.
• The shares were sold at a price of $6.8197 per share.
• The sale was executed on January 6, 2026.
• Following this transaction, Carsten Brunn beneficially owns 323,530 shares of common stock.
• The sale was made to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's explicitly for tax obligations and under a 10b5-1 plan, which typically mitigates negative market perception associated with discretionary insider selling. It's a routine event for executives with equity compensation.

Negatives

• The transaction resulted in a reduction of 23,766 shares from the direct beneficial ownership of the President and CEO.

Risks

• Potential for market misinterpretation of insider selling, despite the stated reason of tax obligations and broker fees, which could lead to undue negative sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is a routine disclosure for public company executives and does not inherently reflect broader industry trends. Such sales for tax purposes are common practice in the biotechnology sector and other industries when restricted stock units vest.

Stakeholder Impact

• Shareholders: The reduction in direct insider ownership is minor and for a routine purpose, unlikely to significantly impact shareholder confidence or company strategy.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations and broker fees upon the vesting of restricted stock units, executed under a Rule 10b5-1 plan. This type of transaction is common and does not typically signal a change in management's confidence in the company's future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Cartesian Therapeutics, RNAC, Carsten Brunn, Insider Transaction, Form 4, Stock Sale, CEO, Tax Obligations, Rule 10b5-1(c)